Regulatory Scrutiny and Strategic Shifts at Novo Nordisk

The Danish pharmaceutical giant Novo Nordisk finds itself navigating a complex landscape of regulatory challenges and strategic realignments. Recent developments present a dual narrative: heightened oversight from U.S. authorities on one hand, and a significant commercial settlement on the other, both centered on its blockbuster GLP-1 medications.

A Landmark Settlement Reshapes Market Dynamics

In a decisive commercial move, Novo Nordisk has transformed a legal adversary into a distribution ally. The company has settled its litigation with the telehealth platform Hims & Hers. The dispute, initiated in February, centered on allegations that the platform was marketing unauthorized, compounded versions of popular GLP-1 drugs.

Under the new agreement, Hims & Hers will cease advertising these lower-cost alternatives and will instead offer Novo Nordisk’s authentic medications at standard market prices. This partnership effectively redirects consumer demand toward the original products and closes a major distribution channel for unregulated copies. The expanded reach is particularly valuable for the tablet form of Wegovy, as Novo Nordisk races to solidify its market position. This urgency is amplified by the anticipated approval of rival Eli Lilly’s oral drug, Orforglipron, expected in the second quarter.

FDA Warning Letter Highlights Reporting Deficiencies

Simultaneously, the company faces intensified regulatory pressure. The U.S. Food and Drug Administration (FDA) issued a warning letter on March 5 following a weeks-long inspection of a New Jersey production facility earlier in 2025. Inspectors cited serious violations, specifically the delayed reporting of severe and unexpected adverse events.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

These incidents, which included strokes and fatalities associated with the active ingredient semaglutid (found in Ozempic and Wegovy), were not submitted within the mandated 15-day period. The FDA identified systemic flaws in Novo Nordisk’s surveillance and data analysis processes, involving both the company and its contractors. In its initial response, Novo Nordisk emphasized that corrective actions have been underway for over a year and stated that the FDA raised no new concerns regarding the actual quality or safety of the medicines. The firm now has 15 business days to submit a comprehensive action plan to avoid further regulatory consequences.

Navigating a Challenging Financial Forecast

These contrasting events unfold against a backdrop of market uncertainty. Following a difficult 2025 that saw the company’s shares lose nearly half their value, a subdued outlook for 2026 is weighing on investor sentiment. Management has provided a currency-adjusted revenue forecast projecting a decline of 5 to 13 percent. This guidance is notably more pessimistic than most market analysts had anticipated.

Attention is now turning to the potential of CagriSema, a successor drug whose approval is anticipated within the next ten months. Clinical trial data has shown it to be more effective than Wegovy. How the newly restructured leadership team intends to balance regulatory compliance with aggressive market defense will be a key focus. Detailed plans are expected to be unveiled at the upcoming annual general meeting in Copenhagen on March 26, 2026.